TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

2nd Annual Genetic Medicines Summit

Cowen’s Genetic Medicines Summit is focused on the development of gene editing therapies, clinical advancement of gene therapy programs, and a focus on the evolving regulatory landscape for these technologies. This summit will be comprised of panels focused on gene editing approaches/technology platforms, gene therapy/editing clinical data and the current regulatory environment for these emerging approaches.

This event follows a successful Gene Therapy: CMC & Regulatory Summit in 2021 which featured discussions on FDA/CBER’s approach to gene therapy reviews given the ongoing COVID pandemic, current and changing requirements for pivotal clinical datasets, the state of gene therapy CMC standards, as well as the role and contribution of patient-focused drug development in gene therapy reviews and access.

*Cowen conferences and events are intended for institutional clients and corporate clients of the firm.  They are not open to media or retail investors.

Medical researcher conducting pharmaceutical research in a lab. Representing innovative therapies for fighting cancer i.e., immuno-oncology
Ahead of the Curve®

Investors Guide to Immuno-Oncology

Close-up photograph of an array of beakers, one being filled with a liquid.
Themes 2023

Therapeutics, Tools and Diagnostic Innovation

Closeup of pipetting sample in a lab setting
Ahead of the Curve®

Profoundly Expanding the Target Space: A Primer on TPD